Velocity’s research site in Omaha frequently conducts clinical trials for a broad range of investigational treatments under the leadership of Velocity’s Chief Physician Officer and principal investigator Brandon J. Essink, MD. Typical studies at this site involve medications for acne, allergies, chronic diseases, depression, high cholesterol, diabetes, infectious diseases, and other conditions. This site also performs vaccine studies for people of all ages. Acquired by Velocity in 2022, the Omaha location was founded in 1999 as the first site and main headquarters for Meridian Clinical Research.
Located just off I-680 in Omaha, near the Northeast corner of 108th and Maple, this location provides services in two buildings and is easily accessible to thousands of patients. All trials conducted at the site are performed in accordance with ICH and FDA guidelines, and in compliance with GCP. Our Omaha team is committed to being a resource for study participants, to providing the highest quality of patient care with compassion and kindness, and to advancing medicine through research.